🔥🐔 BizChicken 🐔🔥
Companies Similar to Kala Pharmaceuticals, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Gilead Sciences, Inc.
Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Atripla, Veklury, Epclusa, Harvoni, Vosevi, Vemlidy, Viread, Yescarta, Tecartus, Trodelvy, Zydelig, Letairis, Ranexa, AmBisome
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for areas of unmet medical need, covering treatments for HIV/AIDS, coronavirus, liver diseases, hematology, oncology, cell therapy, pulmonary arterial hypertension, chronic angina, and serious invasive fungal infections.
About | About | Leadership | Leadership | Leadership | Leadership | Leadership | Leadership | Leadership | Leadership | Leadership | Leadership | Leadership | Directors | Directors | Directors | Directors | Directors | Directors | Directors | Directors | Directors | Directors | Directors | ESG | About | About | About | About | About | About | About | About | About | About | DEI | About | Locations | Contact | Contact | Contact | Careers | Careers | Careers | Careers | Careers | About | About | About | Careers | Jobs | Careers | About | Careers | DEI | Careers | Careers | Careers | Careers | Jobs | Careers | Careers | Careers | DEI | Careers | Careers | Careers | Careers | Careers | Jobs | About | About | About | About | About | About | Careers | Careers | Jobs | Jobs | Careers | Careers | Careers | About | About
Symbol: GILD
Recent Price: $92.01
Industry: Drug Manufacturers - General
CEO: Mr. Daniel P. O'Day
Sector: Healthcare
Employees: 18000
Address: 333 Lakeside Drive, Foster City, CA 94404
Phone: 650 574 3000
Leadership
- Daniel O’Day, Chairman & Chief Executive Officer
- Andrew Dickinson, CFO
- Stacey Ma, Chief Strategy Officer
- Flavius Martin, MD, Chief Operating Officer
- Jyoti Mehra, Chief Medical Officer
- Johanna Mercier,
- Merdad Parsey, MD, PhD, Chief Scientific Officer
- Cindy Perettie, Chief People Officer
- Deborah H. Telman,
- Jacqueline K. Barton, PhD, Professor Emerita, California Institute of Technology
- Jeffrey A. Bluestone, PhD, President and Chief Executive Officer, Sonoma Biotherapeutics Inc.
- Sandra J. Horning, MD, Retired Chief Medical Officer, Roche Inc.
- Kelly A. Kramer, Retired Chief Financial Officer, Cisco Systems Inc.
- Ted W. Love, MD, Chair of Board of Directors, Biotechnology Innovation Organization
- Harish Manwani, Senior Operating Partner, Blackstone Inc.
- Javier J. Rodriguez, Chief Executive Officer, DaVita Inc.
- Anthony Welters, Lead Independent Director; Chairman and Chief Executive Officer, CINQ Care
- John Smith, CEO
- Linda White, Chief Marketing Officer
- Robert Brown, Chief Operating Officer
- Michael Davis, President
- John Doe, CEO
- Jane Smith, CFO
- Emily Johnson, CTO
- Michael Brown, Director of Operations
- Linda Davis, Director
- Alice Johnson, CTO
- Susan Martinez, Chairman
- Jane Doe, CFO
- James Davis, Chairman
- Patricia Miller, President
Last updated: 2024-12-31
Eyenovia, Inc.
Optejet
Eyenovia, Inc. is focused on developing therapeutic solutions for ophthalmic conditions using its proprietary microdose array print platform and Optejet delivery system. It targets conditions like progressive myopia, presbyopia, and mydriasis.
Symbol: EYEN
Recent Price: $0.11
Industry: Biotechnology
CEO: Mr. Michael M. Rowe
Sector: Healthcare
Employees: 57
Address: 295 Madison Avenue, New York, NY 10017
Phone: 917 289 1117
Leadership
- Charles Mather, Chairman of the Board
- Ellen Strahlman, MD, MS, Independent Director
- Sean Ianchulev, MD, MPH, Director
- Michael Geltzeiler, Independent Director
- Rachel Jacobson, Independent Director
- Ram Palanki, PharmD, Independent Director
- Michael Rowe, Director
Last updated: 2024-12-31
KalVista Pharmaceuticals, Inc.
KVD001, sebetralstat, KVD824, Factor XIIa
Kal Vista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on discovering, developing, and commercializing small molecule protease inhibitors for diseases with unmet needs, including hereditary angioedema and diabetic macular edema.
About | About | Management | Directors | About | Contact | Careers | Careers | About | About | About | About | About | About | ESG | About | About | Careers | About | About
Symbol: KALV
Recent Price: $8.39
Industry: Biotechnology
CEO: Mr. Benjamin L. Palleiko
Sector: Healthcare
Employees: 150
Address: 55 Cambridge Parkway, Cambridge, MA 02142
Phone: 857 999 0075
Leadership
- Albert Cha, Member of Board of Directors
- William (Bill) Fairey, Member of Board of Directors
- Benjamin L. Palleiko, Chief Executive Officer and Director
- Brian J. G. Pereira, Member of Board of Directors
- Nancy Stuart, Member of Board of Directors
- Pat Treanor, Member of Board of Directors
- Edward W. Unkart, Member of Board of Directors
Last updated: 2024-12-31
INmune Bio, Inc.
INKmune
INmune Bio, Inc. is a clinical-stage immunotherapy company focused on developing drugs to reprogram the patient's innate immune system for the treatment of hematologic malignancies, solid tumors, chronic inflammation, and Alzheimer's disease.
Symbol: INMB
Recent Price: $4.65
Industry: Biotechnology
CEO: Dr. Raymond Joseph Tesi M.D.
Sector: Healthcare
Employees: 11
Address: 225 NE Mizner Boulevard, Boca Raton, FL 33432
Phone: 858 964 3720
Last updated: 2024-12-31
Regeneron Pharmaceuticals, Inc.
EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb
Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.
About | Leadership | About | History | About | About | Contact | Careers | Careers | Jobs | Jobs | Jobs | Careers | Culture | DEI | Careers | Leadership | Leadership | Leadership | Leadership | Leadership | Leadership | Leadership | Careers | Careers | Careers | Locations | Locations | Locations | Locations | Events | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Jobs | Jobs | Jobs | Jobs | Jobs | Site Map | Careers | About | About | About | About | Jobs | About | Leadership | Careers | Careers | About | Jobs | Jobs | Careers
Symbol: REGN
Recent Price: $702.59
Industry: Biotechnology
CEO: Dr. Leonard S. Schleifer M.D., Ph.D.
Sector: Healthcare
Employees: 14165
Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707
Phone: 914 847 7000
Leadership
- Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
- George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
- Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
- Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
- Leonard Brooks, Senior Vice President, Treasurer
- John Calabro, Senior Vice President, Internal Audit
- Christina Chan, Senior Vice President, Corporate Affairs
- Larry Coury, PhD, Senior Vice President, Associate General Counsel
- Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
- Matthew Everett, Senior Vice President, Global Procurement
- Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
- Rick Hall, Senior Vice President, Human Resources
- Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
- Nouhad Husseini, Senior Vice President, Business Development
- Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
- Melissa Lozner, Senior Vice President, Chief Compliance Officer
- Marion McCourt, Executive Vice President, Commercial
- Bob McCowan, Senior Vice President, IT and Chief Information Officer
- Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
- Richard O’Neal, Senior Vice President, Market Access
- Sally A. Paull, Executive Vice President, Human Resources
- Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
- George Poth, Senior Vice President, Real Estate & Facilities Management
- Alessandra Ravetti, Senior Vice President, Associate General Counsel
- Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
- David Snow, Senior Vice President, Global Head, Dupixent Franchise
- Mark Volpe, Senior Vice President, Tax
- Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
- Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
- Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
- Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
- Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
- Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
- Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
- Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
- Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
- Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
- Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
- Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
- Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
- Christos Kyratsous, PhD, Senior Vice President, Research
- Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
- John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
- Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
- Lynn Macdonald, PhD, Senior Vice President, Research
- Lori Morton, PhD, Senior Vice President, Research
- Andrew Murphy, PhD, Executive Vice President, Research
- Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
- William Olson, PhD, Senior Vice President, Therapeutic Proteins
- Mohammed Shameem, PhD, Senior Vice President, Formulations Development
- L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
- Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
- Neil Stahl, PhD, Executive Vice President, Research and Development
- Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
- Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
- Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
- Frederick Austin, Senior Vice President, Quality Control, Raheen
- Christine Childrose, Senior Vice President, Human Resources and HR Operations
- David Crenshaw, Senior Vice President, Associate General Counsel
- Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
- Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
- Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
- Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
- Scott Oberman, Senior Vice President, Supply Chain Operations
- David Simon, Senior Vice President, IOPS Finance and Business Operations
- Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
- Benjamin Yocum, Senior Vice President, Manufacturing Operations
- James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
- Bonnie L. Bassler, PhD, Director
- Michael S. Brown, MD, Director
- N. Anthony Coles, MD, Chair of the Board
- Joseph L. Goldstein, MD, Director
- Kathryn Guarini, PhD, Director
- Christine A. Poon, Lead Independent Director
- Arthur F. Ryan, Director
- Huda Y. Zoghbi, MD, Director
- Samantha Dickon, Director, Development Program Management
- Gervasio Batista, Sr. Scientist, Neuroscience
- James K. Gibson, Senior Regional Director, Immunology/Pulmonary
- Beth Brause, Director, Field Reimbursement Management
- Eric Prendergast, Director, Pricing Strategy
- Ashley Neff, Manager, Digital Communications
- Shari Loock, Associate Director, Sourcing
- Jennifer Davidson Hamilton, VP and Head of Precision Medicine
- Yi Zhang, Director, Health Economics & Outcomes Research
- Wilson Caldwell III, Director, GCO Vendor & Relationship Management
- David Stein, Director, Medical Operations
- Regeneron, Corporate
- Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
- Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
- Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
- Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
- Jessie Brown, Manager, Integrative Translational Genetics
- Gisu Eom, Lead Cloud DevOps Engineer
- Carmen Kenworthy, Scientist, Velocigene
- Ralph Hazlewood, Sr. Manager, Research Program Management
- Brandy Bennett, Sr. Director, R&D Strategy & Operations
Last updated: 2024-12-31
Blueprint Medicines Corporation
AYVAKIT, BLU-263, Fisogatinib, GAVRETO, BLU-701, BLU-945, BLU-451, BLU-782
Blueprint Medicines Corporation is a precision therapy company focused on developing medicines for genomically defined cancers and blood disorders, including treatment for systemic mastocytosis, gastrointestinal stromal tumors, hepatocellular carcinoma, and non-small-cell lung carcinoma.
About | About | Vision/Values | About | About | About | About | Contact | Contact | Careers | Careers | Careers | Careers | Careers | About | About | About | About | About | About | About | About | About | About | About | About | About | About | Careers | Vision/Values | About | About
Symbol: BPMC
Recent Price: $86.82
Industry: Biotechnology
CEO: Ms. Kathryn Haviland M.B.A.
Sector: Healthcare
Employees: 638
Address: 45 Sidney Street, Cambridge, MA 02139
Phone: 617 374 7580
Last updated: 2024-12-31
EyeGate Pharmaceuticals, Inc.
EGP-437
Eye Gate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye.
About | Vision/Values | Directors | About | Management | Contact
Symbol: EYEG
Recent Price: $35.04
Industry: Biotechnology
CEO: Mr. Stephen From
Sector: Healthcare
Employees: 14
Address: 271 Waverley Oaks Rd Ste 108, Waltham, MASSACHUSETTS 02452
Phone: 17817889043
Leadership
- Paul Chaney, Chairman of the Board
- Morton F. Goldberg, MD, Director
- Praveen Tyle, PhD, Director
- Thomas Balland, Director
- Thomas E. Hancock, Director
- Bernard Malfroy-Camine, PhD, Director
- Mounia Chaoui, PhD, Director
Last updated: 2024-12-31
EyePoint Pharmaceuticals, Inc.
ILUVIEN, YUTIQ, DEXYCU, EYP-1901, YUTIQ50
Eye Point Pharmaceuticals, Inc. develops and commercializes ophthalmic products for treating eye diseases, including innovative treatments like ILUVIEN, YUTIQ, and DEXYCU. Their efforts serve the United States, China, and the United Kingdom, focusing on diseases such as diabetic macular edema and chronic non-infectious uveitis.
About | Contact | Contact | ESG | Careers | Careers | Contact | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | About | About | About
Symbol: EYPT
Recent Price: $7.02
Industry: Biotechnology
CEO: Dr. Jay S. Duker M.D.
Sector: Healthcare
Employees: 121
Address: 480 Pleasant Street, Watertown, MA 02472
Phone: 617 926 5000
Last updated: 2024-12-31
Inhibikase Therapeutics, Inc.
Ik T-148009
Inhibikase Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing therapeutics for Parkinson's Disease and related disorders. Their product pipeline includes treatments for neurological and cancer-related conditions.
About | Leadership | Directors | About | About | About | Contact | Careers | About | About | About | About
Symbol: IKT
Recent Price: $3.24
Industry: Biotechnology
CEO: Dr. Milton H. Werner Ph.D.
Sector: Healthcare
Employees: 8
Address: 3350 Riverwood Parkway SE, Atlanta, GA 30339
Phone: 678 392 3419
Leadership
- Milton H. Werner, Ph.D., President and CEO
- C. Warren Olanow MD, FRCPC, FRCP (Hon.), Medical Consultant and CEO of Clintrex Research Corporation
- Garth Lees-Rolfe, CPA, Chief Financial Officer
- Dan Williams, Controller
- Terence Kelly, Ph.D., Medicinal Chemistry Consultant
- Surendra Singh, Ph.D., Chemistry and Manufacturing Controls
- Merrill M. Kraines, Partner, McDermott, Will & Emery, Outside General Counsel
- Roberto Bellini, Managing Partner at BSQUARED Capital
- Dennis Berman, Serial Entrepreneur
- David Canner, Ph.D., Partner at Soleus Capital
- Roy Freeman, M.D., Professor of Neurology at the Harvard Medical School, Director of the Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center
- Arvind Kush, Chief Financial Officer and Chief Business Officer of Candid Therapeutics
- Amit Munshi, Chief Executive Officer of Orna Therapeutics
Last updated: 2024-12-31
Incyte Corporation
JAKAFI, PEMAZYRE, ICLUSIG
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, with products like JAKAFI, PEMAZYRE, and ICLUSIG for various cancer treatments.
About | Leadership | Contact | Contact | Locations | Contact | Contact | Culture | Jobs | Culture | DEI | News | Events | About | About | Careers | Jobs | Careers | Careers | DEI | Culture | Careers | Culture | DEI | Careers | Locations | Careers | About | About | About | About | About | Careers | About | About | Culture
Symbol: INCY
Recent Price: $68.42
Industry: Biotechnology
CEO: Mr. Herve Hoppenot
Sector: Healthcare
Employees: 2524
Address: 1801 Augustine Cut-Off, Wilmington, DE 19803
Phone: 302 498 6700
Leadership
- Hervé Hoppenot, Chairman and Chief Executive Officer
- Paula J. Swain, Executive Vice President, Human Resources
- Pablo J. Cagnoni, M.D., President, Head of Research and Development
- Steven H. Stein, M.D., Executive Vice President and Chief Medical Officer
- Sheila A. Denton, J.D., Executive Vice President and General Counsel
- Christiana Stamoulis, MBA, Executive Vice President and Chief Financial Officer
- Barry P. Flannelly, PharmD, MBA, Executive Vice President and General Manager, North America
- Denise Brashear, Vice President, Head of Global Communications
- Vijay Iyengar, M.D., Executive Vice President, Global Medical Affairs, Product, and Partnership Strategy (GMAP2S)
- Lee Heeson, Executive Vice President, Head of Incyte International
- Michael Morrissey, Executive Vice President and Head of Global Technical Operations
- Matteo Trotta, MBA, Executive Vice President, General Manager, U.S. Dermatology
- Xiaozhao Wang, Ph.D., Associate Vice President, Head of Medicinal Chemistry
- Julian C. Baker, Managing Partner
- Jean-Jacques Bienaime, Former Chief Executive Officer
- Otis Brawley, M.D., Bloomberg Distinguished Professor of Oncology and Epidemiology
- Paul J. Clancy, Former Executive Vice President and Senior Advisor
- Jacqualyn A. Fouse, Ph.D., Former Chief Executive Officer
- Edmund P. Harrigan, M.D., Former Senior Vice President of Worldwide Safety and Regulatory
- Katherine High, M.D., Former President and Head of Research and Development
- Susanne Schaffert, Ph.D., Former President
Last updated: 2024-12-31
Inovio Pharmaceuticals, Inc.
DNA Medicines
Inovio Pharmaceuticals is a biotechnology company focused on discovering, developing, and commercializing DNA medicines to treat and protect against diseases like HPV, cancer, and infectious diseases. Their platform includes Syn Con designed DNA sequences and CELLECTRA smart devices technology for delivery.
Vision/Values | Leadership | About | Leadership | Vision/Values | About | Contact | Careers | Careers | About | About | About | About | About
Symbol: INO
Recent Price: $1.78
Industry: Biotechnology
CEO: Dr. Jacqueline E. Shea Ph.D.
Sector: Healthcare
Employees: 127
Address: 660 West Germantown Pike, Plymouth Meeting, PA 19462
Phone: 267 440 4200
Leadership
- Jacqueline Shea, Ph.D., President & Chief Executive Officer
- Peter Kies, Chief Financial Officer
- Michael Sumner, MB BS, MBA, Chief Medical Officer
- Laurent Humeau, Ph.D., Chief Scientific Officer; Chairman, Scientific Advisory Board
- Steve Egge, MBA, Chief Commercial Officer
- Rob Crotty, J.D., General Counsel and Chief Compliance Officer
- EJ Brandreth, MBA, Senior Vice President, Quality Assurance
- Shawn Bridy, MA, MBA, Senior Vice President, Business Development
- Cheryl Elder, PharmD, Senior Vice President, Regulatory Affairs
- Robert J. Juba Jr., Senior Vice President, Biological Manufacturing and Clinical Supply Management
- Jeffrey Skolnik, M.D., Senior Vice President, Clinical Development
- Dave Liebowitz, M.D. & Ph.D., Senior Vice President, Early-Stage Clinical Development
- Simon X. Benito, Chairman of the Board, Inovio Pharmaceuticals
- Roger D. Dansey, M.D., Chief Medical Officer at Seagen
- Ann C. Miller, M.D., Former Head of Sanofi Oncology Global Marketing
- Jay Shepard, Former President & CEO of Aravive
- David B. Weiner, Ph.D., Executive Vice President, Director, Vaccine Center, The Wistar Institute
- Wendy L. Yarno, MBA, Former Executive Vice President and Chief Marketing Officer at Merck & Co., Inc.
- Lota S. Zoth, CPA, Former Chief Financial Officer, MedImmune
- Rafi Ahmed, Ph.D., Director, Emory Vaccine Center, Emory University School of Medicine
- Stanley A. Plotkin, M.D., Emeritus Professor, Wistar Institute and University of Pennsylvania; Principal, Vaxconsult
Last updated: 2024-12-31
Kala Pharmaceuticals, Inc.
KPI-012, EYSUVIS, INVELTYS
Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for eye diseases using proprietary mucus penetrating particles technology.
Contact | Careers | Jobs | Careers | Careers | Careers | Careers | Leadership | Careers | Contact | Careers | Careers | Careers | About
Symbol: KALA
Recent Price: $6.87
Industry: Drug Manufacturers - Specialty & Generic
CEO: Mr. Mark T. Iwicki
Sector: Healthcare
Employees: 43
Address: 1167 Massachusetts Avenue, Arlington, MA 02476
Phone: 781 996 5252
Last updated: 2024-12-31
Kodiak Sciences Inc.
KSI-301
Kodiak Sciences Inc., a clinical stage biopharmaceutical company based in Palo Alto, California, specializes in developing therapeutics for retinal diseases. Their lead product candidate, KSI-301, is a potential treatment for various retinal conditions and is currently in Phase IIb/III clinical trials.
Symbol: KOD
Recent Price: $9.97
Industry: Biotechnology
CEO: Dr. Victor Perlroth M.D.
Sector: Healthcare
Employees: 111
Address: 1200 Page Mill Road, Palo Alto, CA 94304
Phone: 650 281 0850
Last updated: 2024-12-31
Kiora Pharmaceuticals, Inc.
KIO-301
Kiora Pharmaceuticals, Inc. develops therapies for ophthalmic diseases, with lead product KIO-301 in Phase 1 trial for vision restoration in degenerative retinal diseases and other products in trials for conditions like rheumatoid arthritis-related ocular issues and corneal wound repair.
Symbol: KPRX
Recent Price: $3.30
Industry: Biotechnology
CEO: Dr. Brian M. Strem Ph.D.
Sector: Healthcare
Employees: 12
Address: 1371 East 2100 South, Salt Lake City, UT 84105
Phone: 781 788 8869
Last updated: 2024-12-31
Karyopharm Therapeutics Inc.
XPOVIO
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing drugs targeting nuclear export for the treatment of cancer and other diseases, with a flagship product named XPOVIO.
Symbol: KPTI
Recent Price: $0.70
Industry: Biotechnology
CEO: Mr. Richard A. Paulson M.B.A.
Sector: Healthcare
Employees: 325
Address: 85 Wells Avenue, Newton, MA 02459
Phone: 617 658 0600
Leadership
- Richard Paulson, President and Chief Executive Officer
- James Accumanno, Chief Compliance Officer
- Brian Austad, Senior Vice President, Pharmaceutical Sciences
- Sohanya Cheng, Chief Commercial Officer and Head of Business Development
- Lisa DiPaolo, Chief Human Resources Officer
- Mike Mano, Senior Vice President and General Counsel
- Michael Mason, Chief Financial Officer
- Stuart Poulton, Chief Development Officer
- Reshma Rangwala, Chief Medical Officer & Head of Research
- Amama Sadiq, Senior Vice President, Global Medical and Scientific Affairs
- Elhan Webb, Senior Vice President, Investor Relations
- Garen Bohlin, Director
- Barry E. Greene, Lead Director
- Mansoor Raza Mirza, MD, Director
- Richard Paulson, MBA, President and Chief Executive Officer
- Christy J. Oliger, Director
- Deepa R. Pakianathan, PhD, Director
- Chen Schor, Director
- Zhen Su, MD, MBA, Director
Last updated: 2024-12-31
Kura Oncology, Inc.
ziftomenib and tipifarnib
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company developing small molecule medicines for the treatment of cancer. It focuses on genetically defined subsets of acute leukemias and has a collaboration with Novartis for certain carcinoma treatments.
Symbol: KURA
Recent Price: $8.51
Industry: Biotechnology
CEO: Dr. Troy Edward Wilson J.D., Ph.D.
Sector: Healthcare
Employees: 142
Address: 12730 High Bluff Drive, San Diego, CA 92130
Phone: 858 500 8800
Last updated: 2024-12-31
Phio Pharmaceuticals Corp.
INTASYL therapeutic platform
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.
Symbol: PHIO
Recent Price: $1.90
Industry: Biotechnology
CEO: Mr. Robert J. Bitterman
Sector: Healthcare
Employees: 8
Address: 257 Simarano Drive, Marlborough, MA 01752
Phone: 508 767 3861
Last updated: 2024-12-31
Ultragenyx Pharmaceutical Inc.
Crysvita, Mepsevii, Dojolvi, Evkeeza, DTX401, DTX301
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the development and commercialization of products for rare and ultra-rare genetic diseases worldwide.
Leadership | About | About | About
Symbol: RARE
Recent Price: $42.27
Industry: Biotechnology
CEO: Dr. Emil D. Kakkis M.D., Ph.D.
Sector: Healthcare
Employees: 1276
Address: 60 Leveroni Court, Novato, CA 94949
Phone: 415 483 8800
Last updated: 2024-12-31
Immix Biopharma, Inc.
IMX-110, IMX-111, IMX-120
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing tissue-specific therapeutics for oncology and inflammation, with clinical trials across the United States and Australia.
Symbol: IMMX
Recent Price: $2.36
Industry: Biotechnology
CEO: Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
Sector: Healthcare
Employees: 14
Address: 11400 West Olympic Boulevard, Los Angeles, CA 90064
Phone: 310 651 8041
Last updated: 2024-12-31
Ventyx Biosciences, Inc.
VTX958
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule product candidates for the treatment of inflammatory diseases and autoimmune disorders. Key products include VTX958 for immune-mediated diseases, VTX002 for ulcerative colitis, and VTX2735 for systemic inflammatory diseases.
Symbol: VTYX
Recent Price: $2.23
Industry: Biotechnology
CEO: Dr. Raju S. Mohan Ph.D.
Sector: Healthcare
Employees: 73
Address: 662 Encinitas Boulevard, Encinitas, CA 92024
Phone: 760 593 4832
Last updated: 2024-12-31